awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q53705974-0323EACE-E3C5-4403-838D-57D6ACDB588F
Q53705974-0323EACE-E3C5-4403-838D-57D6ACDB588F
BestRank
Statement
http://www.wikidata.org/entity/statement/Q53705974-0323EACE-E3C5-4403-838D-57D6ACDB588F
BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers.
P2860
Q53705974-0323EACE-E3C5-4403-838D-57D6ACDB588F
BestRank
Statement
http://www.wikidata.org/entity/statement/Q53705974-0323EACE-E3C5-4403-838D-57D6ACDB588F
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
2d968b7c83b96f353d44942ad3b37b9a9a427b64
P2860
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.